Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email in the first instance.

 Information  X 
Enter a valid email address

Xenova Group plc (XEN)

  Print      Mail a friend

Monday 08 August, 2005

Xenova Group plc

Xenova Group Plc - Result of Court Meeting and EGM

Not for release, publication or distribution in or into Canada,
Australia or Japan

8 August 2005

Xenova Group Plc ("Xenova") is pleased to announce that, at a Court
Meeting and an Extraordinary General Meeting ("EGM") of its
shareholders held earlier today in connection with the recommended
proposal by Celtic Pharma Development UK Plc ("Celtic Pharma") to
acquire Xenova, to be effected by way of a Scheme of Arrangement (the
"Scheme"), all the resolutions proposed received the support of

At the Court Meeting, a majority in number of Xenova's shareholders
who voted (either in person or by proxy), and over 75% by value of
the votes cast, voted in favour of the resolution to approve the
Scheme.  The resolution was accordingly passed.  At the EGM, the
resolution to approve the Scheme and provide for its implementation
was also passed by the requisite majority.

The votes cast for each resolution were as follows:

Court Meeting

Resolution on a poll to approve the Scheme:

By number, 85.82% of shareholders present and voting in person or by
proxy voted for the Resolution, and 14.18% voted against the
Resolution.  By value, 85.96% of shares represented in person or by
proxy were voted in favour of the Resolution and 14.04% were voted
against the Resolution.


Resolution to approve the Scheme and provide for its implementation:

The Resolution was approved on a show of hands.  For information the
proxy vote in favour of the Resolution was 87.52% of votes cast and
against was 12.48% of votes cast.

Completion of the Acquisition remains subject to the satisfaction of
the conditions to the Proposal as set out in the Scheme Document
dated 8 July 2005 and sent to Xenova shareholders.  It is expected
that the Scheme will become effective on 1 September 2005.

Copies of the resolutions passed at the Xenova Court Meeting and EGM,
have been submitted to the Financial Services Authority ("FSA") and
will shortly be available for inspection by the public at the FSA's
Document Viewing Facility which is situated at: Financial Services
Authority, 25 The North Colonnade, Canary Wharf, London E14 5HS (tel.
+44 (0)20 7066 1000) during normal business hours on any weekday
(except public holidays).

Terms used in this announcement shall have the same meanings as set
out in the Scheme Document dated 8 July 2005.

Broadview, a division of Jefferies International Limited, which is
authorised and regulated in the United Kingdom by the Financial
Services Authority, is acting exclusively for Celtic Pharma and no
one else in connection with the Proposal and will not be responsible
to anyone other than Celtic Pharma for providing the protections
afforded to customers of Broadview or for providing advice in
relation to the Proposal, the contents of this announcement or any
transaction or arrangement referred to herein.

Lazard, which is authorised and regulated in the United Kingdom by
the Financial Services Authority, is acting exclusively for Xenova
and no on else in connection with the Proposal and will not be
responsible to anyone other than Xenova for providing the protections
afforded to customers of Lazard or for providing advice in relation
to the Proposal, the contents of this announcement or any transaction
or arrangement referred to herein.


Financial Dynamics: David Yates / Ben Atwell Tel: +44 (0)20 7831 3113



a d v e r t i s e m e n t